Fed’s Powell opens door to potential rate cuts at Jackson Hole
Following these transactions, Huizenga’s direct holdings amount to 50,124 shares. InvestingPro subscribers can access additional insights, including 7 more ProTips and comprehensive financial analysis in the Pro Research Report, helping investors make more informed decisions about Ultragenyx ’s stock potential. InvestingPro subscribers can access additional insights, including 7 more ProTips and comprehensive financial analysis in the Pro Research Report, helping investors make more informed decisions about Ultragenyx’s stock potential.
Following these transactions, Huizenga’s direct holdings amount to 50,124 shares. InvestingPro subscribers can access additional insights, including 7 more ProTips and comprehensive financial analysis in the Pro Research Report, helping investors make more informed decisions about Ultragenyx’s stock potential.
Following these transactions, Huizenga’s direct holdings amount to 50,124 shares.
In other recent news, Ultragenyx Pharmaceutical (NASDAQ:RARE) Inc. reported fourth-quarter 2024 earnings that exceeded expectations, with strong sales from its Crysvita, Dojolvi, and Evkeeza product lines. Canaccord Genuity responded by raising its price target to $136 and maintaining a Buy rating, citing the company’s growth and promising pipeline. The FDA has accepted the Biologics License Application for Ultragenyx’s gene therapy candidate UX111 for Sanfilippo syndrome type A, setting a Prescription Drug User Fee Act action date for August 2025. H.C. Wainwright maintained a Buy rating with a $95 target, emphasizing the importance of this development for the company. Cantor Fitzgerald reiterated an Overweight rating with a $118 price target, highlighting the progress of Ultragenyx’s DTX301 program for Ornithine Transcarbamylase deficiency. Goldman Sachs also maintained a Buy rating with a $78 target, noting Ultragenyx’s fourth-quarter revenue of $164.9 million, which surpassed their estimates. The company’s full-year 2025 revenue guidance remains between $640 million and $670 million. Analysts have expressed optimism about the potential of Ultragenyx’s gene therapy programs and the anticipated success of its clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.